Discover one of our 28 local entrepreneurial communities »
Be the first to know as we launch in new countries and markets around the globe.
Interested in bringing MIT Technology Review to your local market?
Unsupported browser: Your browser does not meet modern web standards. See how it scores »
The human immune system is still the best resource for fighting disease. After a decade of failed promise, drugs that exploit it are finally flooding the market.
With human cells distilled into digital models, testing the effectiveness of a new drug could be as simple as typing a few lines into a computer.
Ted Postol is challenging the government’s claims about a proposed a missile defense system. He’s a prickly character, but he has a track record that’s hard to beat.
Yucca Mountain in Nevada looked like the perfect place to stash the byproducts of nuclear power. Fifteen years and billions of dollars later, it’s not even close to being operational. Is starting from scratch the only option?
The philosophers got it wrong: scientists love new ideas-if they’re right.
It takes years and millions to get a new drug to market. New techniques might burrow through the mountain of genome data and break the bottleneck.
To find disease-causing genes, researchers want access to millions of personal medical records-maybe even yours. Is this necessary science or dubious profiteering?
When fear is the opponent, science doesn’t stand a chance.
Chlorea in Pakistan, Rift Valley fever in Kenya. news of epidemics spreas through the online “CNN of outbreaks.”
By emphasizing challenges to conventional wisdom, the popular press distorts how science really works.